Objective: To investigate the effects of a milk formula supplemented with a a-linolenic acid (ALA) (18:2 n-6/ 18:3 n-3 ratio near 6/1) on plasma and red blood cell (RBC) fatty acids (FAs) in premature infants and compare with a non supplemented formula (18:2 n-6/18:3 n-3 22/1). Design and subjects: Infants of mothers who elected not to breast-feed were randomly assigned to either a high a linolenic formula (HLF: n 31) group or a low a-linolenic formula (LLF: n 32) control group. Infants fed human milk (HM: n 25) were enrolled concurrently as a reference group. Anthropometric and biological measurements were made after two days (D2) and 15 d (D15) of enteral feeding and at the 37th week (W37) of postconceptual age. In HLF, the 18:3 n-3 content was 1.95% of total FAs (0.77% of total energy) and the 18:2 n-6/18:3 n-3 ratio was near 6/1. In LLF, the 18:3 n-3 content was 0.55% of total FAs (0.22% of total energy) and the 18:2 n-6/18:3 n-3 ratio was 22/1. Results: ALA supplementation had minimal effect on the n-6 series, did not alter the anthropometric data and con®rmed the conversion of ALA into docosahexaenoic acid (DHA). Throughout the study, it maintained, the RBC membrane DHA values within the con®dence interval of those obtained in the HM group. Such was not the case with LLF Conclusion: a-linolenic acid supplementation (from Rapeseed oil and in a 18:2 n-6/18:3 n-3 ratio 6) in premature infant formula can contribute ef®ciently to the maintenance of the n-3 status in the premature newborns Descriptors: essential fatty acids; a-linolenic acid; docosahexaenoic acid; plasma; erythrocyte; preterm infant; infant formula; capillary gas chromatography; Rapeseed oil
Introduction
The essentiality of the n-3 fatty acid (FA) family has been documented in humans (Holman et al, 1982; Bjerve et al, 1987) . The dietary requirements for preterm infants are unknown but tissue analysis at different stages of fetal development (Clandinin et al, 1981) suggests that the needs are particularly high. A precise balance between C20 long chain polyunsaturated fatty acids (LCPUFAs) of the n-6 and n-3 series at membrane level is involved in the normal synthesis of both n-3 and n-6 LCPUFAs and eicosanoids of 1, 2 and 3 series. At 7 1/2 ±8 y a higher intelligence quotient was observed in children fed mother's milk after preterm birth than in those who consumed no maternal milk (Lucas et al, 1992) . It has been shown that the n-3 precursors and docosahexaenoic acid (DHA) levels supplied by human milk (HM) result in better visual function (Birch et al, 1992; Carlson et al, 1993) and cerebral development (Farqharson et al, 1992) than do those supplied by regular formulas devoid of n-3 LCPUFAs, and that this is related to higher levels of DHA in red blood cells (RBCs) and cerebral membranes.
There are currently two ways of supplying n-3 FAs in preterm infant formulas: supplementation in the form of LCPUFAs or supplementation with n-3 series precursors. This latter, however, could result in insuf®cient endogenous LCPUFA synthesis. Many studies have tested different a-linolenic acid (ALA) supplying formulas in term or preterm infants. They have demonstrated lower plasma and/or RBC DHA levels than with human milk (Innis et al, 1990; Birch et al, 1992; Ponder et al, 1992) and have raised concerns as to the neonate's ability to desaturate and elongate ALA to DHA. For this reason, preformed LCPUFAs have been preferred as supplements to infant formulas (Koletzko et al, 1989; Birch et al, 1992) . However, adding common ®sh oils containing high levels of eicosapentaenoic acid (EPA) resulted in signi®cant depression of the n-6 FA pathway, mainly by lowering arachidonic acid (AA) in plasma phospholipids and erythrocyte membranes (Birch et al, 1992; Carlson et al, 1992) , and in one study (Carlson et al, 1992) there was a decrease in normalised body weight, length and head circumference. DHA and/or AA supplementation without or with only very low levels of EPA allowed normal growth up to three months in preterm infants (Koletzko et al, 1989; Chirouze et al, 1994) and twelve months in infants born at term (Auestad et al, 1995) without toxic effects, but the supply of pure DHA and AA remains expensive and industrially limited. Thus, ALA supplementation remains of interest, particularly since results obtained using labelled FAs (Carnielli et al, 1996) , indicate that hepatic desaturation and elongation are operative in utero and in neonates.
However it remains to determine if these processes are able to provide adequate amounts of LCPUFAs when premature newborns are supplied with C18 precursors in good conditions. The major questions concern the optimal supply of n-3 and n-6 FAs and the optimal ratio between n-3 and n-6 series in formulas. Recent studies reported (Carlson et al, 1986; Innis et al, 1990 ) that too high levels of linoleic acid (LA) may impair the synthesis of n-3 LCPUFAs (Clark et al, 1992) . The n-3/n-6 balance in our formula was determined by the need to obtain the best ratio of linoleic to a-linolenic bioavailability, considered to be 6/1 in human adults (Lasserre et al, 1985) . Thus, we ®xed the concentration of linoleic acid at 12.5% of total FAs (4.96% of total energy). The high linolenic formula (HLF) contained 1.95% of total FAs as ALA (0.77% of total energy) and the low linolenic formula (LLF) contained 0.55% of total FAs as ALA (0.22% of total energy). A LA/ ALA ratio 6 was easily obtained in HLF with low erucic acid rapeseed (LEAR) oil. To assess the ef®ciency of this ALA supply we compared the effect on plasma and erythrocyte FA composition in two groups of selected preterm infants fed either HLF or regular preterm formula (LLF). This multicentric French study also included a reference group of preterm infants fed human milk.
Methods

Experimental design
Selection of subjects. This multicentric study, approved by the respective ethics committees, included 88 infants from the Pediatric Departments of the Bordeaux, Caen and Montpellier University Hospital Centers. Infants were enrolled when gestational age was less than 34 weeks, birthweight was above the 10th percentile of the national standard curves of birthweight, and clinical conditions permitted early oral feeding. None had metabolic disorders or congenital malformations. From this total population, 63 infants of mothers who elected not to breast-feed were randomly assigned either to the HLF group: n 31; gestational age (mean AE SD), 32.4 AE 1.5 wk; birthweight range: 1300±2200 g or to the LLF (low a linolenic formula, Gallia Nutripharm-France) group: n 32; gestational age (mean AE s.d.), 32.3 AE 1.4 wk; birthweight range: 1270± 2220 g. Infants fed HM were enrolled concurrently as a reference group: n 25; gestational age, 31.2 AE 1.7 wk; birthweight range: 1090±2290 g. All infants of this group received exclusively human milk or exceptionally human milk from lactarium if necessary. They did not receive any formula during this study. Each center randomized independently. Equal numbers of infants (about 30) were programmed in each center. At W37, four infants in HLF group and one in LLF had dropped out and some samples or analysis were lacking for technical reasons explaining the difference between n in Table 2 and Tables 2±5.
Nutrient description. The two formulas were identical for each nutrient parameter except for a-linolenic acid level. Both contained 34 g fat/L, 97 g carbohydrates/L, 20 g proteins/L, and a casein-to-whey ratio of 40:60. The origin of the lipids was cow milk (40%) and vegetable oils (60% including 20% of medium-chain triglycerides).
The 18:2 n-6 content of both formulas was 12.5% of total FAs (4.96% of total energy). 74% of the fat was from identical blends for the two formulas. The 18:3 n-3 content differed: 1.95% of total FAs (0.77% of total energy) in HLF and 0.55% of total FAs (0.22% of total energy) in LLF vs 0.82% of total FAs (0.44% of total energy) in the human milk of this study (Table 1 ). The 18:2 n-6/18:3 n-3 ratio was near 6/1 in HLF; it was 22/1 in LLF. ALA was preferentially located in the sn-2 position of the triglycerides (Rietsch, 1982) in LEAR oil, which was used in this study. Throughout this study, each infant received multivitamins, in particular, vitamins A (7500 UI/d), E (4.7 mg/d), C (75 mg/d) and D (1500 UI/d).
Study design
At birth infants received either fat-free total parenteral or mixed nutrition (allocated preterm formulas cumulated with parenteral nutrition). The fat-free parenteral diet was given for 6 AE 3 and 5 AE 3 d (means AE s.d.) in the HLF and LLF groups, respectively. The ®rst day (D0) with a formula intake of ! 40 Kcal/d was 5 AE 3 and 4 AE 3 d (mean AE s.d.) for HLF and LLF groups, respectively. Oral intake was increased progressively to reach a total amount of 180 ml/ kg/d (140 Kcal/kg/d). D2 and D15 corresponded to the second and ®fteenth day after the ®rst signi®cant formula intake (D0); generally at D2 infants received a minimum of 60 Kcal/d and at D15 complete oral intake (180 ml/kg/d) had been established for one week. The end of the study corresponded to the discharge of the infants at exactly the 37th week of postconception age (W37). Mean durations of 15.6 and 16.2 days elapsed between D15 and W37 in LLF and HLF, respectively, leading to about one month of enteral feeding. An optimum ratio a-linolenate/linoleate in preterm infant formulas C Billeaud et al At D2, D15 and W37 anthropometric measurements of crown-heel length, head circumference, and body weight were recorded, and a blood sample (1.5 mL) was collected by venepuncture with lithium heparinate as the anticoagulant.
Analytical methods
Total plasma cholesterol was determined by an enzymatic method using the BioMe Ârieux kit (Charbonnie Áres, France).
Plasma triglyceride (TG) cholesterol ester (CE) and phospholipid (PL) as well as RBC phosphatidylethanolamine (RBC-PE) FA analysis was performed in the Bordeaux, Caen and Montpellier biochemistry laboratories as described previously (Babin et al, 1993) and the values were expressed as a percentage (wt/wt) of all the FA methyl esters (FAMEs), dimethylacetals detected within a chain length range of 15±24 carbon atoms, and traces of unknown products. The transesteri®ed compounds were separated with a 50 m CP Sil 88 capillary column (Chrompack Les Ulis FRANCE) with the following temperature gradient: 10 C/min from 100±170 C and 2 C/min from 170±200 C, and with hydrogen as carrier gas. Intercenter variation coef®cient (VC) ranged between 2.2±5.7% in plasma PL and 5.5±7.4% in RBC-PE for FAs of main interest.
Statistical methods
Variance analysis was performed on all parameter values after logarithmic transformation of FA percentages and control of normality by the Shapiro±Wilks test. If normality was not accepted or if we did not obtain homoscedasticity of variances, the Kruskall±Wallis tests were used. Variance analyses (ANOVA, one way) allowed comparison between groups (HLF vs LLF) at D2, D15 and W37 as well as comparison of the effect between D2 and D15 and between D15-W37. Preterm infants fed human milk were not randomised for ethical considerations, so no statistical analyses were performed between this group and the two formula groups. However, the 95% con®dence interval of data obtained in the HM group could be considered as the reference value for essential FAs.
Variance analysis also determined the diet effect, the center effect and their interaction. For all parameters, adjusted mean values were calculated for each diet and at each time of sampling (D2, D15 and W37). A multiple stepwise regression method was used to assess interactions between FAs at W37. The two-tailed level of signi®cance was set at P`0.05. All data are presented as mean AE s.d.
Results
Throughout the study, infants were fed exclusively the assigned formula, with the exception of occasional fatfree parenteral nutrition during the ®rst few days of life: 6 AE 3 and 5 AE 3 for HLF and LLF, respectively. Ten infants in HLF group and nine in LLF group received blood transfusions during a period remote from the blood sampling; no signi®cant difference was noted between the volume of packed RBCs (22 AE 19 vs 18 AE 5 ml/kg in HLF and LLF). The end of the study corresponded to the 37th week of conceptual age; at this period the chronological age was 31 AE 9 d and 32 AE 9 for HLF and LLF, respectively. ANOVA of clinical parameters showed the two groups to be statistically indistinguishable from birth to W37 in each center as well as in the combined data. Between D2 and W37, growth rates, namely, weight, length and head circumference gains, were similar. No signi®cant difference between HLF and LLF group concerning clinical data throughout this study.
An optimum ratio a-linolenate/linoleate in preterm infant formulas C Billeaud et al Though statistical analysis did not include the HM group, it clearly appears from ( Table 2 ) that all along the study weight, length and head circumference were the same in the three groups.
n-3 essential fatty acids The ALA level in triglycerides (TG) ( Table 3) was twoand three-fold higher in the HLF than in the LLF group. The difference was highly signi®cant (P`0.0001) at D2, D15 and W37. HLF feeding resulted in a very positive signi®cant effect on ALA incorporation in plasma cholesterol esters (CE) (three-fold higher at D2, 0.32% vs 0.11%, P`0.001; ®ve-fold higher at D15, 0.52% vs 0.10%, P`0.001; three-fold higher at W37, 0.42% vs 0.16%, P`0.001;) (data not shown). There was also a very signi®cant rise in plasma phospholipids (PL) (Table 4) (P`0.0001 at D15 and P`0.001 at W37).
At D2 in plasma PL (Table 4) , the EPA percentage was two-fold higher in the HLF versus the LLF group but the difference was signi®cant only at D15 and W37. The variation between D2 and D15 was also signi®cant between the two groups, supporting the ability of a-linolenate to LCPUFAs conversion. It should be noted, however that the EPA values remained low even in the HLF group (`0.6%). There was a sharp decrease in PL-DHA in the LLF group. This evolution was very signi®cantly different (P`0.0001) from that of the HLF group and led to plasma PL-DHA levels signi®cantly lower both at D15 and W37 (Table 4) . Nevertheless, the PL-DHA level even in the HLF group remained at the lower limit of the HM con®dence interval (HM-CI) values of the group fed human milk.
In RBC, PE-EPA levels (Table 5 ) remained completely within the con®dence interval values of the group fed human milk (D2 and D15) and at the limit of this interval at W37. Between D2 and D15, there was a signi®cant difference in the membranes between the two groups: the PE-DHA decrease in the HLF group was signi®cantly less important (P`0.05) than in the LLF group. Moreover, PE-DHA of HLF group remained stable throughout the study within the HM-CI, while this level decreased in the LLF group and fell below the HM-CI at W37. Two positive results should be noted in the HLF group: reduction of the PE-DHA decrease and maintenance of PE-DHA within the HM-CI throughout the study.
n-6 essential fatty acids In four classes of lipids (plasma TG, CE, PL, and RBC-PE), LA increased from D2 to W37; there was no signi®cant difference between the two formulas. The same pattern was also observed in infants fed HM.
In plasma TG and CE (data not shown), there was no signi®cant variation in the AA level throughout the study. However, the AA level was under the HM-CI in plasma TG at W37 for both formulas. In PL, AA decreased from D2 to D15 in both groups, as in the HM group. The AA level remained signi®cantly lower in the HLF than in the LLF group (at D15: P`0.05 and W37: P`0.01). Perhaps this difference could be considered as the ®rst sign of the interference of n-3 supplementation in the n-6 metabolic pathway. After D2, PL-AA levels of both formula groups remained lower than the HM-CI.
In PE, no difference could be detected between the two groups in terms of the time course of AA variation and AA level. Furthermore, there was no signi®cant difference in AA level between the two groups either at D15 or W37. An optimum ratio a-linolenate/linoleate in preterm infant formulas C Billeaud et al An optimum ratio a-linolenate/linoleate in preterm infant formulas C Billeaud et al
This observation seems to exclude a speci®c adverse effect of a-linolenate supplementation on AA incorporation into erythrocyte membranes. Moreover, throughout the study we observed a constant increase in the level of PE-AA in the HLF group (D2: 13.62%; D15: 14.43%; W37: 15.70%).
No difference could be detected in PL and PE-FAs located either before or after AA in the n-6 pathway (dihomogammalinolenic acid: 20 : 3 n-6, the precursor of series 1 eicosanoids and adrenic acid: 22:4 n-6).
Other fatty acids In all classes of lipids, 16:0 was the same for both formulas and maybe slightly lower than HM in PL. For 18:0, except at D15 in TG and at D2 in PL, the levels were the same for the two formulas. Oleic acid was signi®cantly higher at D15 and W37 in TG, PL and CE for HLF. In plasma CE, 16:1 n-7 was signi®cantly lower at D15 (P`0.05) in HLF (4.72 AE 1.81%) vs LLF (5.81 AE 1.81%) and descreased more quickly in the HLF group from D2 (8.05 AE 2.97%) to D15 (4.72 AE 1.81%) (P`0.01), con®rm-ing the importance of this acid as a nutritional index of essential fatty acid (EFA) de®ciency.
The Mead acid, which is considered a good indicator of EFA de®ciency, did not signi®cantly differ between the two groups, in constrast to palmitoleic acid, which seems a more pertinent marker of n-3 EFA status. These two FAs decreased regularly for both formulas, as in the HM group, from D2 to W37 in all the lipid classes; thus excluding the possibility of EFA de®ciency in this study.
Plasma total cholesterol
In spite of the greater amounts of cholesterol supplied by human milk (19 mg/100 kcal., namely about 26 mg/kg/d after D15) compared to both formulas (6.5 mg/100 kcal., namely about 8.9 mg/kg/d after D15), total plasma cholesterol levels did not differ among the three groups (3.63 AE 0.26, 3.22 AE 0.22 and 3.10 AE 0.20 mmoL/L for HM, HLF and LLF, respectively). This suggests a good homeostatic equilibrium between oral cholesterol intake and its endogenous biosynthesis in the three groups.
Discussion
It should be noted that the level of ALA in LLF used in our study was lower than the current recommendations. However, ALA levels in the range of that of LLF were usual in France in regular preterm formulas when our study was designed and LLF should be considered as a formula commonly used in France at that time. Moreover, it was reported that 5 out of 20 formulas analysed in a very recent study (Chardigny et al, 1996) do not meet the LA/ALA ratio of ESPGAN recommendations. Table 2 indicates that in the time course of the study, our experimental diet did not affect the anthropometric parameters, particularly growth and head circumference.
Our ®rst biological results concern the bioavailability of a-linolenate and its conversion to higher n-3 FAs. Our data con®rm a very signi®cant effect of ALA supplementation on ALA incorporation in plasma TG, PL and CE, which was much higher in the HLF group than in the LLF throughout the study. This result re¯ects the good absorption and utilization of this FA by preterm infants in the supplemented formula. Moreover, the ratio of a-linolenate levels in HLF (1.95% of total FAs) to LLF (0.55% of total FAs), which was 3.5/1, was found almost unmodi®ed in plasma TG. Given the preferential situation of ALA in the sn-2 position of LEAR oil (55%) (Rietsch, 1982) , this observation is in complete agreement with data obtained in humans (Descomps et al, 1989) showing that fatty acid absorption and incorporation in circulating TG is facilitated by the sn-2 position via the 2-monoglyceride pathway in enterocytes. In PL, at D15 and W37, the EPA and DHA levels were very signi®cantly higher in the group fed HLF than in the group fed LLF, providing indirect but indisputable evidence that ALA to DHA conversion was ef®-cient at that time in preterm infants. However the earlier rise of EPA in plasma PL possibly re¯ects a lower ef®-ciency of the so-called`d4 desaturase' process than the other steps of the n-3 pathway in the preterm infant or a difference in`redistribution process' between EPA and DHA. Moreover, multiple regression analysis con®rmed a direct positive correlation between PL-EPA and TG-ALA (re¯ecting absorbed ALA) at D15: EPA 0.22 ALA 0.14 (R 0.66; P`0.05) and at W37: EPA 0.23 ALA 0.08 (R 0.72; P`0.05); however, there was no direct correlation between Pl-DHA and TG-ALA. This fact suggests that the last step between EPA and DHA was not only related to the ALA intake but that it is certainly complex.
In RBC-PE the effectiveness of HLF is proven by its ability to prevent PE-DHA from falling between D2 and D15 (P`0.05). Moreover, a-linolenate supplementation maintained PE-DHA throughout the study within the con®dence interval values of the group fed human milk. Given that a delay of 15 d was necessary to observe a signi®cant difference for DHA in plasma PL between the HLF and LLF groups, it can be postulated that a longer period of HLF feeding would have been necessary to signi®cantly differentiate PE-DHA in RBC. Our study in preterm infants was in agreement with recent results in very low birth weight premature infants (Carnielli et al, 1996) using stable isotope-labeled FAs, supporting conversion of 18:3 n-3 to DHA and highlighting that the`d4 step' is very complex.
The incidence of a-linolenate supplementation upon the n-6 series was minimal. The AA level in plasma PL was slightly but signi®cantly lower in the HLF group at W37, but the importance of this observation is limited since neither 20:3 n-6, 22:4 n-6 nor AA in RBC-PE were affected. Furthermore, AA supply by HM probably explains in part the generally higher AA concentration observed in the TG and PL of the HM group. Data from theoretical studies (Clark et al, 1992; Gibson et al, 1994) has been used to de®ne the optimal ratio of LA/ALA in infant formulas; this ratio was determined to be between 4/ 1 and 6/1 for term infants to increase DHA synthesis from ALA. Our data for preterm infants show that a LA/ALA ratio of 6/1 seems to be the lower limit below which AA synthesis may be altered.
We also monitored the EFA de®ciency index, and vitamin E status since o3 supplementation was reported sometimes to alter the redox status. The vitamin E status was not altered by ALA supplementation (data not shown). The 20:3 n-9/20:4 n-6 ratio was proposed by Holman (Holman, 1973) as an index of EFA de®ciency. In all our groups, this ratio remained within the recommended range ( 0.4); moreover it was in agreement with Mendy et al, (1970) and it was much lower than the upper limit: 0.11 and 0.03 at D15 and W37, respectively, in plasma PL of the HM group and 0.07 in the HLF group (Table 4) . A rise in the 22:5 n-6/22:6 n-3 ratio could also be indicative of 22:5 n-6 substitution to 22:6 n-3 in cases of n-3 LCPUFA de®ciency. In the HLF group, this ratio remained at the limit of the HM-CI, indicating a suf®cient supply of n-3 LCPUFAs; whereas a 1.5±2 fold increase appeared in the LLF group, showing the drift out of the reference status which occurred in this group.
This multicentric study, including a large number of preterm infants from different geographic regions, was designed to conform with the above mentioned recommendations. It demonstrated that when formula is supplemented with ALA from LEAR oil, with a LA/ALA ratio of 6 (LA: 12.5% of total FAs, or 4.96% of energy vs ALA: 1.95% of total FAs, or 0.77% of energy), biological values and DHA levels are near those found in infants fed human milk. It prevents RBC PE-DHA from falling between D2 and D15 and preserves the main C20 participants of the n-6 pathway at the membrane level. It is noteworthy that the present supplementation did not affect the anthropometric parameters. It thus appears that formulas such as LLF (ALA: 0.22% of energy and LA:ALA ratio 22:1) are inadequate to maintain LCPUFA status in preterm newborns. Our data comparing FA parameters obtained with HLF and LLF support the recommendations for ALA supplementation in infant formulas. While this manuscript was in preparation, a paper appeared (Jensen et al, 1996) emphasizing again the importance of dietary LA/ALA ratio for DHA status mainenance in term infants.
